Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
about
Progress in tumor-associated macrophage (TAM)-targeted therapeutics.What's New in SCLC? A Review.Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical modelsPhase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
P2860
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lurbinectedin induces depletio ...... c adenocarcinoma mouse models.
@en
Lurbinectedin induces depletio ...... c adenocarcinoma mouse models.
@nl
type
label
Lurbinectedin induces depletio ...... c adenocarcinoma mouse models.
@en
Lurbinectedin induces depletio ...... c adenocarcinoma mouse models.
@nl
prefLabel
Lurbinectedin induces depletio ...... c adenocarcinoma mouse models.
@en
Lurbinectedin induces depletio ...... c adenocarcinoma mouse models.
@nl
P2093
P2860
P50
P356
P1476
Lurbinectedin induces depletio ...... ic adenocarcinoma mouse models
@en
P2093
Carlos María Galmarini
Carmen Cuevas
Francesca Sarno
Manuel Hidalgo
María José Guillén
María Virtudes Céspedes
Pablo Avilés
Patricia Álamo
P2860
P304
P356
10.1242/DMM.026369
P577
2016-10-20T00:00:00Z